Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wormwood (Artemisia absinthium) is a perennial herb traditionally used for digestive disorders and recently investigated for its immunomodulatory properties in inflammatory bowel disease (IBD). In clinical trials for Crohn's disease, wormwood has demonstrated a significant steroid-sparing effect, allowing patients to taper off corticosteroids while maintaining or achieving clinical remission. Its mechanism of action is thought to involve the suppression of pro-inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), and it has also been observed to improve mood and quality of life in patients, potentially through its effects on the gut-brain axis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wormwood.